Renal Cancer - Results from #2200

Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. February 10, 2021

Prognostic value of lymphocyte-to-monocyte ratio previously determined to surgery in patients with non-metastatic renal cell carcinoma: A systematic review and a prisma-compliant meta-analysis. February 10, 2021

Stereotactic body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer: a systematic review. February 10, 2021

Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction. February 9, 2021

Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. February 9, 2021

Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. February 9, 2021

Targeted therapy response in early versus late recurrence of renal cell carcinoma after surgical treatment: A propensity score-matched study using the Korean Renal Cancer Study Group database. February 9, 2021

The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy. February 9, 2021

A Novel mRNA-miRNA Regulatory Sub-Network Associated With Prognosis of Metastatic Clear Cell Renal Cell Carcinoma. February 8, 2021

Percutaneous radiofrequency for the treatment of small renal masses: Analysis of outcomes and complications after 10 years of experience. February 8, 2021

A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety. February 8, 2021

Comparison of oncologic outcomes between partial nephrectomy and radical nephrectomy in patients who were upstaged from cT1 renal tumor to pT3a renal cell carcinoma: an updated systematic review and meta-analysis. February 5, 2021

Transcriptome Analyses Identify an RNA Binding Protein Related Prognostic Model for Clear Cell Renal Cell Carcinoma. February 5, 2021

The Clinical Significance of DNA Damage Repair Signatures in Clear Cell Renal Cell Carcinoma. February 5, 2021

Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma. February 4, 2021

Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. February 4, 2021

Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. February 4, 2021

Long-Term Oncologic Outcomes After Laparoscopic and Robotic Tumor Enucleation for Renal Cell Carcinoma. February 3, 2021

A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy. February 3, 2021

Mapping the immune environment in clear cell renal carcinoma by single-cell genomics. February 3, 2021

Page 111 of 456